CBD is not converted to THC in rats: A framework interpretation and discussion

Vacek, Jan; Papoušková, Barbora; Polanská, Hana; Hönigová, Kateřina; Storch, Jan; Babula, Petr; Masařík, Michal

doi:10.1016/j.euroneuro.2021.04.003

Cited by 4 publications

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This analytical method for the determination of CBD in the blood and brain tissue was also used in our previous work [ 46 ]. Following a comment [ 47 ] on our previous article [ 46 ], a reanalysis of the method was performed and a variable conversion of CBD to THC on SPE columns in the range of 0–10% was found. To determine any levels of THC in the measured samples, deuterated THC (THC-3d) was added to the samples and the same calibration series were prepared as for CBD.…”

Section: Methodsmentioning

confidence: 99%

Anticonvulsive Effects and Pharmacokinetic Profile of Cannabidiol (CBD) in the Pentylenetetrazol (PTZ) or N-Methyl-D-Aspartate (NMDA) Models of Seizures in Infantile Rats

Uttl

Hložek

Mareš

et al. 2021

IJMS

View full text Add to dashboard Cite

In spite of use of cannabidiol (CBD), a non-psychoactive cannabinoid, in pediatric patients with epilepsy, preclinical studies on its effects in immature animals are very limited. In the present study we investigated anti-seizure activity of CBD (10 and 60 mg/kg administered intraperitoneally) in two models of chemically induced seizures in infantile (12-days old) rats. Seizures were induced either with pentylenetetrazol (PTZ) or N-methyl-D-aspartate (NMDA). In parallel, brain and plasma levels of CBD and possible motor adverse effects were assessed in the righting reflex and the bar holding tests. CBD was ineffective against NMDA-induced seizures, but in a dose 60 mg/kg abolished the tonic phase of PTZ-induced generalized seizures. Plasma and brain levels of CBD were determined up to 24 h after administration. Peak CBD levels in the brain (996 ± 128 and 5689 ± 150 ng/g after the 10- and 60-mg/kg doses, respectively) were reached 1–2 h after administration and were still detectable 24 h later (120 ± 12 and 904 ± 63 ng/g, respectively). None of the doses negatively affected motor performance within 1 hour after administration, but CBD in both doses blocked improvement in the bar holding test with repeated exposure to this task. Taken together, anti-seizure activity of CBD in infantile animals is dose and model dependent, and at therapeutic doses CBD does not cause motor impairment. The potential risk of CBD for motor learning seen in repeated motor tests has to be further examined.

show abstract

Section: Methodsmentioning

confidence: 99%